Ionis Pharmaceuticals (IONS) analyst forecast and price target
Analyst forecast
Consensus of 27 analyst ratings
Based on 10 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $100.00 | Sep 24, 2026 |
| JP Morgan | Maintained | Overweight | $70.00 from $76.00 | Sep 22, 2026 |
| Guggenheim | Maintained | Buy | $80.00 from $89.00 | Sep 15, 2026 |
| Barclays | Maintained | Overweight | $85.00 from $90.00 | Sep 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $100.00 from $115.00 | Sep 8, 2026 |
| Canaccord Genuity | Maintained | Buy | $85.00 from $95.00 | Sep 8, 2026 |
| BMO Capital | Maintained | Market Perform | $54.00 from $61.00 | Sep 8, 2026 |
| Goldman Sachs | Maintained | Neutral | $56.00 from $69.00 | Sep 8, 2026 |
| Morgan Stanley | Maintained | Overweight | $104.00 from $110.00 | Sep 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $115.00 | Sep 4, 2026 |
| BMO Capital | Maintained | Market Perform | $61.00 from $60.00 | Sep 4, 2026 |
| Needham | Maintained | Buy | $86.00 | Sep 4, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $115.00 | Aug 31, 2026 |
| BMO Capital | Initiated Coverage | Outperform → Market Perform | $60.00 | Aug 19, 2026 |
| JP Morgan | Maintained | Overweight | $76.00 from $72.00 | Aug 3, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $115.00 from $125.00 | Jul 30, 2026 |
| Wells Fargo | Maintained | Overweight | $95.00 from $100.00 | Jul 30, 2026 |
| Guggenheim | Maintained | Buy | $89.00 from $106.00 | Jul 21, 2026 |
| Wolfe Research | Downgraded | Outperform → Peer Perform | — | Jul 16, 2026 |
| RBC Capital | Maintained | Outperform | $85.00 from $100.00 | Jul 13, 2026 |
Frequently asked questions
What is the price target for IONS stock?
The average 12-month analyst price target for Ionis Pharmaceuticals (IONS) is $81.50, with a high estimate of $104.00 and a low of $54.00, across 10 analysts.
Is IONS a buy, sell, or hold?
Analysts covering Ionis Pharmaceuticals currently average a Buy rating: 22 buy, 5 hold and 0 sell, from 27 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for IONS?
The average price target of $81.50 implies 90.87% upside from the last price of $42.70.
What is the latest analyst rating on IONS?
On Sep 24, 2026, HC Wainwright & Co. maintained Ionis Pharmaceuticals at Buy with a price target of $100.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.